Combination therapy with tremelimumab and durvalumab significantly improves survival in liver cancer patients compared to standard sorafenib treatment.

Morgan Cantley, PharmD, BCOP, shares key insights about the HER2-targeting antibody drug conjugate trastuzumab deruxtecan.

Many adults remain unaware of HPV’s cancer risks, highlighting the urgent need for increased awareness.

IDSA updated cUTI guidelines for men and women emphasize antibiotic selection, transition to oral therapy, and optimal treatment duration.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia…

Tenapanor offers a new approach to managing hyperphosphatemia in dialysis patients, balancing effectiveness with pill burden and cost considerations.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

The designation is supported by promising results from the ongoing phase 1/2 BEACON clinical trial.